Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells

Werner B, Dittmann S, Funke C, Ueberla K, Piper C, Niehaus K, Horstkotte D, Farr M (2014)
Inflammation Research 63(4): 267-276.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Werner, Bianca; Dittmann, Sven; Funke, Carsten; Ueberla, Klaus; Piper, Cornelia; Niehaus, KarstenUniBi; Horstkotte, Dieter; Farr, Martin
Abstract / Bemerkung
The coxsackie and adenovirus receptor (CAR) mediates the entry of coxsackievirus B (CVB) and adenovirus into host cells and is, therefore, a key determinant for the molecular pathogenesis of viral diseases such as myocarditis. The aim was to investigate the influence of HMG-CoA reductase inhibitor lovastatin on CAR expression in endothelial cells. Human umbilical vein endothelial cells (HUVECs) were exposed to different concentrations of lovastatin (0.05-5 mu mol/l) for up to 48 h. Alterations in CAR expression were examined by quantitative real-time PCR (qRT-PCR) and flow cytometry. In addition, after treatment with 1 mu mol/l lovastatin for 48 h, HUVECs were infected for 8 h with CVB3 and virus replication was detected by qRT-PCR using viral-specific TaqMan probes. We found that lovastatin decreases CAR mRNA expression by up to 80 % (p < 0.01) and CAR protein expression by up to 19 % (p < 0.01), in a concentration-dependent manner. Moreover, virus replication of CVB3 was significantly inhibited after lovastatin treatment (p < 0.05). The signaling mechanism of CAR down-regulation by lovastatin depends on the Rac1/Cdc42 pathway. This study shows for the first time that lovastatin reduces the expression of CAR and subsequently the replication of CVB3 in HUVECs.
Stichworte
Statin; Coxsackie and adenovirus receptor; Inflammation; Viral myocarditis; Coxsackievirus B3
Erscheinungsjahr
2014
Zeitschriftentitel
Inflammation Research
Band
63
Ausgabe
4
Seite(n)
267-276
ISSN
1023-3830
eISSN
1420-908X
Page URI
https://pub.uni-bielefeld.de/record/2673595

Zitieren

Werner B, Dittmann S, Funke C, et al. Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells. Inflammation Research. 2014;63(4):267-276.
Werner, B., Dittmann, S., Funke, C., Ueberla, K., Piper, C., Niehaus, K., Horstkotte, D., et al. (2014). Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells. Inflammation Research, 63(4), 267-276. doi:10.1007/s00011-013-0695-z
Werner, Bianca, Dittmann, Sven, Funke, Carsten, Ueberla, Klaus, Piper, Cornelia, Niehaus, Karsten, Horstkotte, Dieter, and Farr, Martin. 2014. “Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells”. Inflammation Research 63 (4): 267-276.
Werner, B., Dittmann, S., Funke, C., Ueberla, K., Piper, C., Niehaus, K., Horstkotte, D., and Farr, M. (2014). Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells. Inflammation Research 63, 267-276.
Werner, B., et al., 2014. Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells. Inflammation Research, 63(4), p 267-276.
B. Werner, et al., “Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells”, Inflammation Research, vol. 63, 2014, pp. 267-276.
Werner, B., Dittmann, S., Funke, C., Ueberla, K., Piper, C., Niehaus, K., Horstkotte, D., Farr, M.: Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells. Inflammation Research. 63, 267-276 (2014).
Werner, Bianca, Dittmann, Sven, Funke, Carsten, Ueberla, Klaus, Piper, Cornelia, Niehaus, Karsten, Horstkotte, Dieter, and Farr, Martin. “Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells”. Inflammation Research 63.4 (2014): 267-276.

2 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection.
Lange PT, Darrah EJ, Vonderhaar EP, Mboko WP, Rekow MM, Patel SB, Sidjanin DJ, Tarakanova VL., J Virol 90(7), 2016
PMID: 26739055

53 References

Daten bereitgestellt von Europe PubMed Central.

The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.
Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM., Proc. Natl. Acad. Sci. U.S.A. 98(26), 2001
PMID: 11734628
Receptor for the group B coxsackieviruses and adenoviruses: CAR.
Carson SD., Rev. Med. Virol. 11(4), 2001
PMID: 11479928
Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers.
Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, Schoemaker R, Veghel R, Houtsmuller A, Schultheiss HP, Lamers J, Poller W., Gene Ther. 6(9), 1999
PMID: 10490761
HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses.
Tomko RP, Xu R, Philipson L., Proc. Natl. Acad. Sci. U.S.A. 94(7), 1997
PMID: 9096397
Isoform-specific expression of the Coxsackie and adenovirus receptor (CAR) in neuromuscular junction and cardiac intercalated discs.
Shaw CA, Holland PC, Sinnreich M, Allen C, Sollerbrant K, Karpati G, Nalbantoglu J., BMC Cell Biol. 5(1), 2004
PMID: 15533241
The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain.
Honda T, Saitoh H, Masuko M, Katagiri-Abe T, Tominaga K, Kozakai I, Kobayashi K, Kumanishi T, Watanabe YG, Odani S, Kuwano R., Brain Res. Mol. Brain Res. 77(1), 2000
PMID: 10814828
Expression of coxsackievirus and adenovirus receptor in hearts of rats with experimental autoimmune myocarditis.
Ito M, Kodama M, Masuko M, Yamaura M, Fuse K, Uesugi Y, Hirono S, Okura Y, Kato K, Hotta Y, Honda T, Kuwano R, Aizawa Y., Circ. Res. 86(3), 2000
PMID: 10679478
Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections.
Noutsias M, Fechner H, de Jonge H, Wang X, Dekkers D, Houtsmuller AB, Pauschinger M, Bergelson J, Warraich R, Yacoub M, Hetzer R, Lamers J, Schultheiss HP, Poller W., Circulation 104(3), 2001
PMID: 11457744
Myocarditis.
Feldman AM, McNamara D., N. Engl. J. Med. 343(19), 2000
PMID: 11070105
Viral infection and the pathogenesis of dilated cardiomyopathy.
Martino TA, Liu P, Sole MJ., Circ. Res. 74(2), 1994
PMID: 8293557
Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P., Circulation 93(5), 1996
PMID: 8598070
The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review.
D'Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, Di Sciascio G., Heart 85(5), 2001
PMID: 11302994

D, 2004
Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction.
Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP., Circulation 107(22), 2003
PMID: 12771005
HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
Grundy SM., N. Engl. J. Med. 319(1), 1988
PMID: 3288867
Spectrum of pleiotropic effects of statins in heart failure.
Mathur N, Ramasubbu K, Mann DL., Heart Fail Clin 4(2), 2008
PMID: 18433695
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.
Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW., Science 275(5304), 1997
PMID: 9036860
Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms.
Hirase T, Kawashima S, Wong EY, Ueyama T, Rikitake Y, Tsukita S, Yokoyama M, Staddon JM., J. Biol. Chem. 276(13), 2001
PMID: 11139571
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.
Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K., Nat. Med. 6(9), 2000
PMID: 10973320
Low-density lipoprotein-independent effects of statins.
Davignon J, Laaksonen R., Curr. Opin. Lipidol. 10(6), 1999
PMID: 10680049
In vivo half-life of a protein is a function of its amino-terminal residue.
Bachmair A, Finley D, Varshavsky A., Science 234(4773), 1986
PMID: 3018930
The N-end rule pathway of protein degradation.
Varshavsky A., Genes Cells 2(1), 1997
PMID: 9112437
Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells.
Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM., J. Biol. Chem. 277(18), 2002
PMID: 11839765
Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells.
Funke C, Farr M, Werner B, Dittmann S, Uberla K, Piper C, Niehaus K, Horstkotte D., J. Gen. Virol. 91(Pt 8), 2010
PMID: 20392896
Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors.
Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg RW., J. Infect. Dis. 175(3), 1997
PMID: 9041347
A novel cell entry pathway for a DAF-using human enterovirus is dependent on lipid rafts.
Stuart AD, Eustace HE, McKee TA, Brown TD., J. Virol. 76(18), 2002
PMID: 12186914
Regulation of the mevalonate pathway.
Goldstein JL, Brown MS., Nature 343(6257), 1990
PMID: 1967820
Rho GTPases and signaling networks.
Van Aelst L, D'Souza-Schorey C., Genes Dev. 11(18), 1997
PMID: 9308960
HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.
Suh JW, Choi DJ, Chang HJ, Cho YS, Youn TJ, Chae IH, Kim KI, Kim CH, Kim HS, Oh BH, Park YB., J. Korean Med. Sci. 25(1), 2009
PMID: 20052342
Protein lipidation in cell signaling.
Casey PJ., Science 268(5208), 1995
PMID: 7716512
Modulation of tight junction function by G protein-coupled events.
Hopkins AM, Li D, Mrsny RJ, Walsh SV, Nusrat A., Adv. Drug Deliv. Rev. 41(3), 2000
PMID: 10854690
p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho.
Wildenberg GA, Dohn MR, Carnahan RH, Davis MA, Lobdell NA, Settleman J, Reynolds AB., Cell 127(5), 2006
PMID: 17129786
Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane.
Utech M, Ivanov AI, Samarin SN, Bruewer M, Turner JR, Mrsny RJ, Parkos CA, Nusrat A., Mol. Biol. Cell 16(10), 2005
PMID: 16055505
Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins.
von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M., Trends Microbiol. 4(10), 1996
PMID: 8899962
Structural basis of the Rho GTPase signaling.
Hakoshima T, Shimizu T, Maesaki R., J. Biochem. 134(3), 2003
PMID: 14561717
The evolutionary history of effectors downstream of Cdc42 and Rac.
Cotteret S, Chernoff J., Genome Biol. 3(2), 2002
PMID: 11864373
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H., Circ. J. 73(2), 2008
PMID: 19060417
The coxsackie-adenovirus receptor induces an inflammatory cardiomyopathy independent of viral infection.
Yuen S, Smith J, Caruso L, Balan M, Opavsky MA., J. Mol. Cell. Cardiol. 50(5), 2011
PMID: 21352828
Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis.
Kallewaard NL, Zhang L, Chen JW, Guttenberg M, Sanchez MD, Bergelson JM., Cell Host Microbe 6(1), 2009
PMID: 19616768
Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo.
Shi Y, Chen C, Lisewski U, Wrackmeyer U, Radke M, Westermann D, Sauter M, Tschope C, Poller W, Klingel K, Gotthardt M., J. Am. Coll. Cardiol. 53(14), 2009
PMID: 19341864

U, Circulation 109(21 Suppl 1), 2004
Effects of HMG-CoA reductase inhibitor on experimental autoimmune myocarditis.
Liu X, Li B, Wang W, Zhang C, Zhang M, Zhang Y, Xia Y, Dong Z, Guo Y, An F., Cardiovasc Drugs Ther 26(2), 2012
PMID: 22382902
Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation.
Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL, Gale M Jr., Proc. Natl. Acad. Sci. U.S.A. 100(26), 2003
PMID: 14668447

T, J Exp Clin Med 3(1), 2011
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 24316867
PubMed | Europe PMC

Suchen in

Google Scholar